A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)

BACKGROUND: Neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACR) are the standard treatments for esophageal squamous cell carcinoma (ESCC). However, the 5-year overall survival (OS) rate is still far from satisfactory. In recent years, immune checkpoint inhibitors (ICIs) have show...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ann Transl Med
Главные авторы: Zheng, Yan, Liu, Xian-Ben, Sun, Hai-Bo, Xu, Jinliang, Shen, Sining, Ba, Yu-Feng, Yan, Ming, Qin, Zimin, Liu, Bao-Xing, Wang, Zong-Fei, Liu, Shi-Lei, Zhang, Rui-Xiang, Chen, Pei-Nan, Liang, Guang-Hui, Yuan, Dongfeng, Li, Zhen-Xuan, Liu, Qi, Wang, Hao-Ran, Li, Hao-Miao, Lv, Hongwei, Ma, Xiaochao, Zhu, Jianping, Yu, Yong-Kui, Xing, Wen-Qun
Формат: Artigo
Язык:Inglês
Опубликовано: AME Publishing Company 2021
Предметы:
Study Protocol
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7859818/
https://ncbi.nlm.nih.gov/pubmed/33553366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-5404
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы